CGF Securities Issues ''Buy'' Recommendation for Nymox.

BOCA RATON, Fla. -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that CGF Securities, LLC, issued a "Buy" recommendation in a new Update Report on Nymox. Nymox Pharmaceutical Corporation is a biopharmaceutical company specializing in the research and development of therapeutics and diagnostics for the aging population with an emphasis on Alzheimer's disease. CGF Securities Healthcare Analyst Clifford P. Murray, M.D. wrote the report which is available at www.cgfsecurities.com. CGF Securities, LLC, is a diversified financial services firm which provides corporate, private client and institutional services including investment and merchant banking, brokerage and institutional sales and research.

More information about Nymox is available at www.nymox.com, email: [e-mail], or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in NYMOX's filings with the United States Securities and Exchange Commission and other regulatory authorities. CGF Securities, LLC, a subsidiary of Capital Growth Financial, Ltd. (the "Firm") currently makes a market in these securities. The Firm, its officers, directors, analysts or employees may effect transactions in and have long or short positions in the securities mentioned herein.